SSSW(688399)2024-04-26 09:21Financial Performance - The company reported no cash dividends or stock bonuses for the fiscal year, with retained earnings carried forward to the next year[6]. - The company has not achieved profitability since its listing[4]. - The company's operating revenue for 2023 was CNY 403,179,297.92, a decrease of 92.72% compared to CNY 5,534,792,784.45 in 2022[22]. - The net profit attributable to shareholders for 2023 was CNY -373,811,354.73, reflecting a decline of 120.45% from CNY 1,827,900,394.20 in the previous year[22]. - The cash flow from operating activities for 2023 was CNY -113,143,705.50, a decrease of 105.76% compared to CNY 1,964,878,081.19 in 2022[22]. - The basic earnings per share for 2023 was CNY -6.38, down 120.46% from CNY 31.18 in 2022[23]. - The company reported a net loss of CNY -429,201,076.61 after deducting non-recurring gains and losses, a decline of 124.31% from CNY 1,765,592,194.56 in 2022[22]. - The company's total assets at the end of 2023 were CNY 3,906,413,426.27, a decrease of 20.13% from CNY 4,890,999,989.86 at the end of 2022[22]. - The net assets attributable to shareholders decreased by 9.87% to CNY 3,405,103,905.11 at the end of 2023 from CNY 3,778,150,295.65 at the end of 2022[22]. Revenue and Growth - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[15]. - User data showed an increase in active users, reaching 500,000, which is a 20% increase compared to the previous year[15]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[15]. - New product launches are expected to contribute an additional 200 million RMB in revenue, with a focus on innovative diagnostic technologies[15]. - The company achieved operating revenue of CNY 403.18 million in 2023, a decrease of 92.72% year-on-year; excluding public health control business, regular business revenue grew by 34.17%[33]. Research and Development - The company is investing in R&D, allocating 15% of its revenue towards the development of new technologies and products[15]. - The R&D expenditure as a percentage of operating revenue increased to 33.62%, up 30.26 percentage points from 3.36% in 2022[23]. - R&D expenses totaled CNY 135.53 million, accounting for 33.62% of the operating revenue, reflecting a strong commitment to innovation[34]. - The company has a robust R&D team capable of conducting product development in molecular biology, immunology, pharmacology, and pathology[34]. - The company has shifted its R&D focus from quantity to quality, optimizing resource allocation in its R&D management[66]. Market Expansion and Strategy - Market expansion plans include entering two new international markets, aiming for a 5% market share within the first year[15]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB for potential targets[15]. - The company is focused on integrating its product offerings and expanding its market through strategic partnerships and acquisitions[35]. - The company is pursuing internationalization as a strategic path, recognizing its manufacturing capabilities and technology levels in the global market[51]. - The company plans to implement a global marketing strategy by selectively targeting key market areas based on the development of its overseas business[131]. Corporate Governance - A standard unqualified audit report was issued by the accounting firm for the company[5]. - The company has established a comprehensive governance structure, ensuring compliance with laws and regulations, and maintaining independent operations from its controlling shareholder[136]. - The independent directors of the company have played a crucial role in enhancing the transparency and fairness of the compensation system, ensuring that performance-based pay is implemented effectively[42]. - The company aims to improve corporate governance and protect the interests of shareholders, especially minority shareholders, through the active role of independent directors[43]. - The company has maintained compliance with corporate governance laws, ensuring fair information disclosure to all shareholders[198]. Social Responsibility and ESG - The company has actively engaged in social responsibility initiatives, receiving the "Social Public Welfare Award" from the China Cancer Foundation for six consecutive years[39]. - The company emphasizes ESG integration into its operations, focusing on environmental protection and social responsibility[184]. - The company has implemented measures to ensure that all waste is either comprehensively utilized or safely disposed of, with hazardous waste managed by qualified entities[187]. - The company has achieved zero solid waste discharge during operations by utilizing qualified hazardous waste disposal units and recycling materials[194]. - The company donated 1.4972 million in cash and 42,000 in material support for various charitable activities during the reporting period[195]. Risks and Challenges - The company experienced a significant decline in revenue primarily due to the decrease in income from COVID-related products and services[24]. - The company is facing risks related to significant revenue decline and potential losses due to global economic downturns and intensified industry competition[81]. - There is a risk of intensified market competition as higher industry profit margins attract more capital into the sector[84]. - The company is exposed to risks from potential changes in national policies affecting the medical device industry, which could impact operations[89]. - The company faced risks related to new product development, including potential failures due to insufficient foresight and long development cycles of 3-5 years[83]. Employee and Management Structure - The total number of employees in the parent company is 595, and in major subsidiaries is 89, resulting in a total of 684 employees[170]. - The company emphasizes employee training and development, implementing annual training plans to enhance overall employee skills and capabilities[173]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to RMB 13.27 million[156]. - The total remuneration for core technical personnel at the end of the reporting period was RMB 4.97 million[157]. - The company has a diverse management team with members holding positions in various biotechnology and pharmaceutical companies[152].